BioLargo provides review of 2024, insights for coming year

CEO Dennis Calvert said, in part, “As we advance into the second half of 2025, we extend our heartfelt thanks for your continued support and belief in BioLargo’s (BLGO) mission to create breakthrough solutions for a greater good while building value for our stockholders. This year, we are witnessing the culmination of years of strategic investment and R&D, with several of our business units approaching inflection points in the commercialization of the technology they were formed to develop and implement…We are intentionally building a diversified portfolio where each business unit – advanced medical, energy storage, water treatment, odor control, and engineering services – can thrive individually while contributing to BioLargo’s collective growth. Our diversification strategy has proven especially wise over the past two quarters as we continue to advance our commercial efforts into meaningful and high growth business opportunities like Clyra and our Cellinity battery technology. Our business model leverages our core competency of science and engineering while it reduces risk through diversification, creates multiple paths to revenue, and maximizes shareholder value. We believe that our solution in each of these verticals has the potential to be a market leader in its own right, and together they embody our mission to solve some of the world’s toughest challenges with sustainable innovation.”